- 66 Downloads
Synopsis: Bumetanide1 is a potent ‘loop’ diuretic for the treatment of oedema associated with congestive heart failure, hepatic and renal diseases, acute pulmonary congestion and premenstrual syndrome and in forced diuresis during and after surgery. Bumetanide may be given orally, intravenously or intramuscularly and produces a rapid and marked diuresis, and increased urinary excretion of sodium, chloride and other electrolytes (within 30 minutes) which persists for 3 to 6 hours. Its principal site of action is on the ascending limb of the loop of Henle, with a secondary action on the proximal tubule.
Pharmacologically, bumetanide is about 40- fold more potent thanfrusemide (furosemide), with the exception of its effects on urinary potassium excretion where its potency is lower. Studies in patients with oedema due to congestive heart failure, pulmonary oedema or hepatic disease show that oral or intravenous bumetanide 0.5 to 2 mg/day produces results comparable to those with frusemide 20 to 80 mg/day. In acute pulmonary oedema, intravenous bumetanide produces a very rapid diuresis. Higher doses of bumetanide may be required (up to 15 mg/day) in patients with chronic renal failure or nephrotic syndrome. In these patients muscle cramps are not uncommon with bumetanide, but glomerular filtration rates are unaffected. In most studies, diuretic effects were accompanied by decreased bodyweight, abdominal girth and improvements in a variety of haemodynamic parameters.
Comparison of bumetanide with frusemide at a dose ratio of 1: 40 reveals no significant differences in clinical response with the exception of renal disease, where patients with oedema appear to respond better to bumetanide.
Combination with thiazide diuretics enhances the clinical response to bumetanide. Potassium supplements and spironolactone may be beneficial additions to bumetanide where patients at risk of hypokalaemia can be identified. Clinically important side effects are infrequent, with audiological impairment occurring to a lesser extent than with frusemide. Bumetanide thus offers an important alternative to frusemide when a ‘loop’ diuretic is indicated.
Pharmacodynamic Studies: Bumetanide is a potent ‘loop’ diuretic, which produces a marked dose-related diuresis and urinary excretion of sodium and chloride in man over a dose range of 0.5 to 3.0mg. On a milligram-for-milligram basis bumetanide is 40-fold more potent than frusemide, although the dose-response curves for the two drugs are not parallel outside this dose range, and in cases such as renal impairment, where high doses may be used, a ratio of 40: 1 may be misleading. Total maximal diuresis increases by about 5- to 10-fold in healthy volunteers and patients, and urinary sodium and chloride excretion by about 10- to 20-fold, after both oral and intravenous doses of bumetanide. The fractional excretion rate of sodium is increased from less than 3% to up to 25%. The comparability of the total effects of these 2 dose routes reflects almost complete gastrointestinal absorption of oral doses. Bumetanide produces marked diuresis in states of hydropenia as well as in states of aqueous diuresis. Onset of diuresis in patients with oedematous states given oral bumetanide occurs within 30 minutes, reaches peak activity at 60 to 180 minutes and has a duration of 5 to 6 hours. Intravenous doses elicit effects within 10 minutes, and reach peak effects at 15 to 45 minutes.
The increase in total potassium excretion is about 3-fold, therefore the sodium/potassium excretion ratio is increased with bumetanide. This occurs to a greater extent with bumetanide than with frusemide or hydrochlorothiazide, thereby giving it a lesser theoretical kaliuretic potential than the latter 2 drugs. Increases in urinary calcium, magnesium and phosphate excretion also parallel those of sodium and water excretion, but may be greater than with frusemide. Urine osmolality is decreased with bumetanide. Excretion of titratable acid, bicarbonate, and ammonium ions are all increased, with negligible effects on urine pH - although renal tubular fluid may be acidified. Hyperuricaemia is commonly observed.
Bumetanide enhances renal blood flow and increases kidney volume. This precedes diuresis and is probably subject to control or mediation by local prostaglandin, kinin and kallikrein activity. Altered renal haemodynamics are probably responsible for increased plasma renin activity but are not essential for the diuretic effects of bumetanide. Glomerular filtration rate is usually unaffected, even in patients with renal insufficiency. Probenecid has been shown to inhibit the effects of bumetanide, despite raised plasma concentrations of the diuretic, but probably only after repeated or high doses. It is unlikely that bumetanide has any effect on carbonic anhydrase. Bumetanide has been shown to directly inhibit the electrolyte transport in the ascending limb of the loop of Henle. Furthermore, indirect evidence is suggestive of an additional proximal tubular site of action. Bumetanide directly inhibits the sodium-potassium-chloride cation co-transport systems in a number of cellular models and is about 60 to 100 times more potent than frusemide in such studies.
Pharmacokinetic Studies: Peak plasma concentrations of bumetanide following oral doses of 0.5 to 2mg occur after 0.5 to 2 hours and are dose related (30 to 80 Mg/L) in healthy volunteers. Absorption of bumetanide is rapid and almost complete (bioavailability up to 95%) in contrast to some commercially available frusemide formulations. A widely varying volume of distribution of 12 to 35L has been reported. Bumetanide is 93 to 95% protein bound in plasma with no appreciable binding to erythrocytes.
In man, renal elimination accounts for about half the total plasma clearance rate of 200 to 250 ml/min, the rest being cleared by hepatic metabolism or via the biliary route. Urinary recovery of 80% at 48 hours is composed primarily of unchanged drug, with unconjugated alcohols being the principal urinary metabolites. The elimination half-life of bumetanide is about 1 to 1.5 hours in healthy volunteers.
In patients with chronic hepatic or renal disease both the plasma protein-bound fraction and clearance rates may be decreased, and the half-life of bumetanide increased. There appear to be no important pharmacokinetic interactions between bumetanide and either digoxin or warfarin, or when potassium is added to or combined with bumetanide.
Therapeutic Trials: Clinical trials with bumetanide have been extensively carried out in patients with oedematous states due to congestive heart failure, liver and renal disease. However, these studies suffer from inadequate standardisation of disease severity and of the subjective and objective measurements used to gauge clinical respose to bumetanide. Overall there appears to be no significant difference between the effects of bumetanide and frusemide (in a dose ratio of 1:40), with the effects of both drugs being somewhat attenuated upon repeated doses but stabilising at above basal levels of diuresis and saliuresis. Continued efficacy for periods up to 18 months has been shown with bumetanide.
In patients with congestive heart failure, oral and intravenous bumetanide 0.5 to 2 mg/day produces a rapid increase in urinary water and electrolyte excretion, along with decreased abdominal girth, bodyweight and hepatomegaly. Where congestive heart failure is complicated by hypertension, ischaemic or valvular heart disease or non-obstructive hypertrophic cardiomyopathy, bumetanide may reduce mean arterial blood pressure, pulmonary and systemic arterial resistance, right atrial pressure, pulmonary capillary venous pressure, left ventricular end-diastolic pressure and heart rate without affecting cardiac work indexes or blood gases. At higher doses bumetanide is also effective in most congestive heart failure patients where renal insufficiency is present. In infants, a suboptimal dose of 0.015 mg/kg given as an oral solution produced both short and long term diuresis and saliuresis with no significant adverse effects.
Patients with acute pulmonary oedema or hypertension experience the necessarily rapid and intense diuresis and electrolyte excretion following intravenous and intra-arterial administration of bumetanide 1 to 3mg. However, very severely diseased patients may be resistant to clinical improvements.
Advanced liver disease of various aetiology accompanied by oedema or ascites has been successfully treated with bumetanide 1 to 4 mg/day, with the elimination of ascites and oedema, and decreases in bodyweight and abdominal girth. A successful response may be achieved in patients with both hepatic disease and renal insufficiency but, in such patients, only data on intra-arterial administration are currently available. Addition of spironolactone in patients with advanced liver disease prevents the plasma potassium decreases seen during bumetanide therapy but may not increase the diuretic response.
Bumetanide is usually an effective diuretic in patients with oedema associated with chronic renal failure and nephrotic syndrome, especially where other diuretic therapy has failed or aggravated the renal impairment. However, higher doses (up to 15 mg/day) may be necessary. In cases of severe renal insufficiency, bumetanide may not produce adequate diuresis, although natriuresis may be pronounced. Overall, comparative studies indicate an advantage in favour of bumetanide over frusemide in both short and long term use in these patients. Such high doses are more commonly associated with muscle cramps than in patients with other oedematous conditions, but glomerular filtration rate is usually unaffected and may even increase with bumetanide. However, there is some evidence to suggest that in these patients the relative potency of frusemide compared with bumetanide may be greater than the 1:40 ratio reported in other patients.
Other conditions in which bumetanide has proven useful include forced diuresis after surgery (cardiac, urological, and for Dupuytren’s contracture) and reduction of oedema in premenstrual tension, although experience in these fields is limited.
The few controlled studies where potassium was given either as a supplement to or in combination with bumetanide therapy do not indicate any advantages for potassium replacement. However, in studying this controversial area little attempt has been made to identify those patients particularly ‘at risk’ of hypokalaemia.
When bumetanide is combined with the thiazide diuretics there is a distinct supraadditive effect without affecting glomerular filtration rate. Further addition of spirono-lactone does not confer any clinical advantages, but helps allay the increased hypokalaemic effect of combined ‘loop’ and thiazide diuretic therapy.
Side Effects: The incidence of clinical side effects during treatment with bumetanide is relatively low and is approximately equivalent to that observed with frusemide (8.8% vs 7.4%, respectively). Impaired hearing and vertigo occur to a lesser extent than with frusemide (1.7% vs 3.0%) and audiometric studies have confirmed this difference between the ototoxic potential of the drugs. Muscle cramps occur in some patients treated with high doses of bumetanide, and mammary ‘abnormalities’, encephalopathy and hepatic oedema have occasionally been reported.
Abnormal laboratory results occur in 45 to 50% of patients treated with bumetanide and frusemide, but may be pre-existent in these patients and are rarely of clinical or statistical significance. Changes in serum electrolyte, creatinine and uric acid concentrations reflect the basic pharmacological activity of the drugs. Liver function test and haematological abnormalities are infrequent, although hyperglycaemia occurs in 6.6% and 10.1% of patients treated with bumetanide or frusemide, respectively. However, the possibility of a direct association between altered carbohydrate metabolism and bumetanide administration remains speculative. Despite a lesser kaliuretic effect than frusemide, bumetanide is not associated with a lower incidence of hypokalaemia.
Dosage and Administration: Bumetanide is usually administered as an oral dose of 0.5 to 2 mg/day to patients with oedematous states although this may be exceeded, especially in cases of renal oedema where doses of up to 15 mg/day may be necessary. Intravenous or intramuscular bumetanide 0.5 to 2 mg/day is usually reserved for those patients in whom oral administration is impractical, or where a very prompt onset of action is necessary, as in cases of acute pulmonary oedema.
KeywordsRenal Blood Flow Frusemide Ethacrynic Acid Postgraduate Medical Journal Potassium Excretion
Unable to display preview. Download preview PDF.
- Abaza, H.H.; Hammouda, N.; El-Gohary, Y.; Abd Rabbo, H. and Aziz, Y.: Effective management of ascites of schistosomal hepatic fibrosis with the new saluretic, bumetanide. Bulletin Alexandra Faculty of Medicine 8: 193–199 (1977Google Scholar
- Abidi, S.E.; Miller, R.P.; Jacknowitz, A. and Quick, C.A.: Increased inner ear fluid gentamicin levels in the presence of loop diuretics. American Pharmaceutical Association, Academy of Pharmaceutical Sciences, 29th National Meeting, San Antonio, Texas, Volume 10, p. 90 (1980Google Scholar
- Allison, M.E.M. and Kennedy, A.C.: Diuretics in chronic renal disease. A study of high dosage frusemide. Clinical Science 41: 171 (1971Google Scholar
- Almeida, T.R. and Barros, P.P.: Tratamiento de la hipertension arterial con bumetanida. A Folha Medica 80: 1–4 (1980Google Scholar
- Andersch, B.; Hahn, L.; Wendestam, C.; Öhman, R. and Abrahamsson, L.: Treatment of premenstrual tension syndrome with bromocriptine. Acta Endocrinologica Scandinavica 88: 165–174 (1978aGoogle Scholar
- Bjorndal, N. and Lynggaard, F.: Bumetanide (Burinex) in high oral dosage in patients with chronic renal insufficiency. Uges-krift for Laeger 140: 1084–1087 (1978Google Scholar
- Bourke, E.: Diuresis and serum electrolyte levels: A comparative clinical study of bumetanide (Burinex), bumetanid-KCl (Burinex K) and frusemide. Clinical Trials Journal 11:9-13 1974Google Scholar
- Brater, D.C.; Kaojaren, S.; Chennavasin, P.; Burdette, A. and Anderson, S.: Comparison of pharmacokinetics of bumetanide to furosemide in subjects and patients with congestive heart failure. Pharmacologist 24: 175 (1982Google Scholar
- Brater, D.C.; Fox, W.R. and Chennavasin, P.: Interaction studies with bumetanide and furosemide. Effects of probenecid and of indomethacin on response to bumetanide in man. Journal of Clinical Pharmacology 21: 647–653 (1981Google Scholar
- Brown, R.D.: Comparisons of the acute effects of intravenous furosemide and bumetanide on the cochlear action potential (N,) and on the AC cochlear potential (CM) at 6KHz in cats, dogs and guinea pigs. Scandinavian Audiology (Suppl. 14): 71–83 1981aGoogle Scholar
- Brunkhorst, R.; Müller-Ott, K.; Gutsche, H.V. and Niedermayer, W.: Effect of furosemide, bumetanide and piretanide on the sensor of the tuboglomerular feedback mechanism; in Robinson and Hawkins (Eds) Dialysis Transplantation Nephrology pp. 613–616 (Pitman Medical, London 1979Google Scholar
- Candia, O.A. and Schoen, H.F.: Selective effects of bumetanide on chloride transport in bullfrog cornea. American Journal of Physiology 234: 297–301 (1978Google Scholar
- Comis, S.D.; Leng, G. and Pratt, S.R.: The effects of frusemide, bumetanide and piretanide on the guinea pig cochlea and auditory nerve. Scandinavian Audiology (Suppl. 14): 85–93 1981Google Scholar
- De Ritis, G.; Pietropaoli, P. and Sarcinelli, L.: In dagine clinica sull’effecto diuretico della ‘bumetanide’. Acta Anaesthesiol-ogica Italica 26: 211–216(1975Google Scholar
- Duchin, K.L. and Hutcheon, D.E.: Effect of bumetanide on renal cortical blood flow. Journal of Clinical Pharmacology 15: 558–559 (1975Google Scholar
- Fausti, S.A.; Frey, R.H.; Rappaport, B.Z. and Erickson, D.A.: An investigation of the effect of bumetanide on high frequency (8-20KHz) hearing in humans. Journal of Auditory Research 19: 243–250 (1979Google Scholar
- Gatta, A.; Grassetto, M.; Merkel, G; Zuin, R.; Milani, L. and Ruol, A.: Effect of intrarenal administration of bumetanide on renal haemodynamics and function in patients with liver cirrhosis. International Journal of Clinical Pharmacology Research 1: 199–208 (1981Google Scholar
- Goldberg, M.; McCurdy, D.K.; Fortz, E.L. and Bluemle, L.W.: Effects of ethacrynic acid (a new saluretic agent) on renal diluting and concentrating mechanisms. Evidence for site of action in the loop of Henle. Journal of Clinical Investigation 43: 201–216(1964Google Scholar
- Haas, M. and McManus, T.J.: Bumetanide inhibits (NA+K+2C1) co-transport at a chloride site. American Journal of Physiology 245: 235–240 (1983Google Scholar
- Hall, S.: Hyperosmolar non-ketotic diabetic syndrome precipitated by treatment with diabetics. British Medical Journal 284: 665(1982Google Scholar
- Hayes, A.H.; Shiroff, R.A.; Limjuco, R.A. and Schneck, D.W.: Effect of bumetanide on the renal excretion of digoxin. Clinical Pharmacology and Therapeutics 25: 228 (1979Google Scholar
- Herlong, H.F.; Hunter, F.M.; Koff, R.S. and Maddrey, W.C.: A comparison of bumetanide and furosemide in the treatment of ascites. Cooperative Study. Journal of Clinical Pharmacology 21: 701–705 (1981Google Scholar
- Higashio, T.; Abe, Y. and Yamamoto, K.: Renal effects of bumetanide. Journal of Experimental Pharmacology and Therapeutics 207: 212–220(1978Google Scholar
- Hioki, M.; Ariga, T. and Shindo, H.: Gas Chromatographic determination of bumetanide and its urinary excretion in healthy volunteers. Annals of the Sankyo Research Laboratory 26: 85–93 (1974Google Scholar
- Holazo. A.A.; Gustafson, J.H.; Young, R.L. and Parsonnet, M.: A bioavailability study of intravenous, intramuscular and oral bumetanide. American Pharmaceutical Association, Academy of Pharmaceutical Sciences, 31st National Meeting, Orlando, Florida, Volume 11, p. 141 1981Google Scholar
- Holland, S.D. and Williamson, H.E.: Probenecid inhibition on bumetanide-induced natriuresis in the dog. Proceedings of the Society of Experimental Biology and Medicine 161: 299–302 (1979Google Scholar
- Hropot, M. and Muschawek, R.: Micropuncture studies with neutral salts of so-called ‘high ceiling’ diuretics. Archives of Pharmacology 287: 56(1975Google Scholar
- Hutcheon, D.E.; Pocelinko, R. and Duchin, K.L.: Bumetanide in the treatment of hypertension; in Scriabine and Sweet (Eds) New Antihypertensive Drugs, pp. 323–336 (Spectrum Publications, New York 1976Google Scholar
- Imai, M.: Effect of bumetanide and furosemide on the thick ascending limb of Henle’s loop of rabbits and rats perfused invitro.European Journal of Pharmacology 41: 409–416 (19Google Scholar
- Insinna, F.; Lombardo, S. and Giarusso, P.: La bumetanide nella practica clinica anche in corso di diabete. Rivista di Patologica e Clinica 36: 185–200 (1981Google Scholar
- Jayme, D.W.: Diuretic-sensitive K+fluxes in mouse L cell fibroblasts. Federation Proceedings of the American Society of Experimental Biology 40: 1783 1981Google Scholar
- Karcn, F.E. and Lasagna, L.: Evaluating adverse drug reactions; in Davis (Ed.) Adverse Drug Reaction Bulletin, pp. 204–207 (Newcastle upon Tyne Regional Postgraduate Institute for Medicine and Dentistry 1976Google Scholar
- Kaul, B.; Davidow, B. and Hutcheon, D.: Digoxin kinetics after the administration of chlorothiazide, furosemide and bumetanide. Clinical Research 25: 585A (1977Google Scholar
- Kramer, H.J.: Effects of bumetanide on sodium transport of the isolated frog skin and on renal Na-K-ATPase. Pharmacology 14:481-489 1976Google Scholar
- Kusakari, J.; Kambayashi, J.; Ise, I. and Kawamoto, K.: Reduction of the endocochlear potential by the new loop diuretic, bumetanide. Acta Otolaryngologica 86: 336–341 (1978Google Scholar
- Lant, A.F.: Methodology in clinical pharmacology: Assessment of diuretics; in Jouhar and Grayson (Eds) International Aspects of Drug Evaluation and Usage, pp. 127–142 (Churchill Livingstone, London 1973Google Scholar
- Lawson, D.H.; Boddy, K.; Gray, J.M.B.; Mahaffey, M. and Mills, E.: Potassium supplements in patients receiving long-term diuretics for oedema. Quarterly Journal of Medicine, New Series 45: 469–478 (1976Google Scholar
- Lemieux, G.; Beauchemin, M.; Gougoux, A. and Vinay, P.: Treatment of nephrotic oedema with bumetanide. Canadian Medical Association Transactions 125: 1111–1117 (1981Google Scholar
- McInnes, G.T.; Thomson, A.H.; Rapeport, W.G. and Cook, A.: Loop diuretics — infusion or bolus? Clinical Science 63: 33–34 (19Google Scholar
- Maack, P.; Kohl, F.-V. and Rüdiger, H.W.: Diagnostische und therapeutische einer pulmona Drucksenkung durch Bume-tanid (Fordivran®). Therapiewoche 30: 5785–5788 (1980aGoogle Scholar
- Maack, P.; Kohl, F.V. and Rüdiger, H.W.: Hämodynamische sofortwirkung von Bumetanid bei Patienten mit pulmonaler Hypertonie. Therapiewoche 30: 889–895 (1980bGoogle Scholar
- Maddedu, P.; Glorioso, N.; Dessi Fulgheri, P. and Rappelli, A.: Effects on bumetanide and postura on plasma prorenin in normal subjects. Studi Sassaresi 57: 297–304 (1979Google Scholar
- Magnussen, M.P. and Eilertsen, E.: Species differences in the diuretic activity and metabolism of bumetanide. Naunyn-Schmiedeberg’s Archives of Pharmacology 282 (Suppl.): 61 (1974Google Scholar
- Masuda, H.; Maiata, K. and Kimura, K.: The safety test of bumetanide. Annual Reports of the Sankyo Research Laboratories 25: 110–128(1973Google Scholar
- Murphy, J.E.; Maneksha, S. and Brodie, N.H.: Patient preference for a combined diuretic/potassium regimen. Burinex K. Journal of International Medical Research 3: 104–107 (1975Google Scholar
- Ohtani, I.; Ohtsuki, K.; Omata, T.; Ouchi, J. and Saito, T.: Interaction of bumetanide and kanamycin. Journal for Otorhin-olaryngology and its Borderlands 40: 216–225 (1978Google Scholar
- Olesen, K.H.; Sigurd, B.; Hesse, B.; Steiness, E. and Leth, A.: Diuretic action of bumetanide in congestive heart failure. Postgraduate Medical Journal 51: 54–63 (1975Google Scholar
- Ortiz Gonzàlez, A.O. and Mendez Martin, A.M.: Acute effects of bumetanide in healthy subjects. A comparative study with furosemide. Medicina Clinica 72: 259–264 (1979Google Scholar
- Palfrey, H.C.; Feit, P.W. and Greengard, P.: cAMP-stimulated cation cotransport in avian erythrocytes: Inhibition by ‘loop’ diuretics. American Journal of Physiology 238: 139–148 (1980bGoogle Scholar
- Papazoglou, N.; Andriopoulos, J.; Prionas, D. and Tsopras, A.: Clinical observations of a new diuretic (bumetanide). Hellenic Cardiological Review 16: 288–291 (1975Google Scholar
- Pedrinelli, R.; Magagua, A.; Arzilli, F.; Sassano, P. and Salvetti, A.: Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension. Clinical Pharmacology and Therapeutics 6: 722–731 (1980Google Scholar
- Pentikäinen, P.J.; Neuvonen, P.J.; Kekki, M. and Penttilä, A.: Pharmacokinetics of intravenously administered bumetanide in man. Journal of Pharmacokinetics and Biopharmaceutics 6: 219–228 (1980Google Scholar
- Pierucci, A.; Simonetti, B.M.; Stirati, G. and Cinotti, G.A.: Effects of bumetanide upon PRA and urinary kallikrein excretion in normal subjects before and after indomethacin treatment. Minerva Neurologica 27: 421–424 (1980Google Scholar
- Purohit, R.; Auld, W.H.R.; Marcantonio, L.A.; Murdoch, W.R. and Skellern, G.G.: The effect of hepatic and renal disease on the administration of the diuretic bumetanide. Scottish Medical Journal 27: 92 (1982Google Scholar
- Puschett, J.B.; Sylk, D. and Teredesai, P.P.: Uncoupling of proximal sodium bicarbonate from sodium phosphate transport by bumetanide. American Journal of Physiology 235: 403–408 (1978Google Scholar
- Sández Macho, M. and Sánchez Salorio, M.: Hypotensive action of bumetanide on ocular tension. Medicina Clinica 69: 106–108 (1977Google Scholar
- Segal, M.B. and Pollay, M.: The secretion of cerebrospinal fluid: in Bhito et al. (Eds) The Ocular and Cerebrospinal Fluids. Proceedings of a Fogarty International Symposium. Experimental Eye Research 25 (Suppl.): 127–148 (1977Google Scholar
- Silver, M.R.; Moller, M.B.; Owen Black, F.; Wall, C. and Puschett, J.B.: Effects of furosemide and bumetanide on auditory and vestibular function in normal human volunteers. Kidney International 23: 135 (1983Google Scholar
- Steward, R.; Michels, R.; Balakumaran, K.; Lubsen, J. and Hugenholtz, P.G.: Comparative diuretic and haemodynamic effects of bumetanide and Lasix in acute myocardial infarction with left ventricular failure. Abstracts of the European Congress of Cardiology, Paris, p. 187 (Jun 1980Google Scholar
- Stone, W.J.; Bennett, W.M. and Cutler, R.E.: Long-term bumetanide treatment of patients with edema due to renal disease. Cooperative studies. Journal of Clinical Pharmacology 21: 587–590 (1981Google Scholar
- Velasquez, M.T.; Wan, S.H. and Maronde, R.F.: Bumetanide-induced rise in plasma renin activity. Clinical Pharmacology and Therpeutics 24: 186–191 (1978Google Scholar
- Vincent, M.E. and Hutcheon, D.E.: Studies on the sites of renal hydrogen ion secretion in response to bumetanide in the dog. Federation Proceedings 40: 648 (1981Google Scholar
- Whelton, A.: Long-term bumetanide treatment of renal edema. Comparison with furosemide. Journal of Clinical Pharmacology 21: 591–598 (1981Google Scholar
- Wynn, V.; Harper, P. and Freire, A.: Bioavailability of potassium from Burinex K. Journal of International Medical Research 2: 314–316 (1974Google Scholar